MEA Bovine Respiratory Disease Treatment Market

MEA Bovine Respiratory Disease Treatment Market Size (2022 to 2027)

The size of the Middle-East and Africa Bovine Respiratory Disease Treatment Market size has been estimated at USD 4.00 million in 2022. It is projected to reach USD 10.87 million by 2027, growing at a CAGR of 22.1% during the forecast period.

Bovine respiratory disease (BRD) has a multifactorial, polymicrobial etiology. Organisms known to be related to BRD include bacteria and viruses. BRD is a shared health problem for both dairy and beef cattle, ensuing in economic loses. There are many factors that combine to cause disease. No two scenarios are precisely the same but they often culminate in severe and fatal bacterial pneumonia.

Bovine respiratory disease complex (BRDC) is a substantial reason of mortality and morbidity in cattle; resulting into loss of million dollars annually for the dairy and beef industries, even with the use of vaccines and antibiotics. 

This research report segmented and sub-segmented the MEA Bovine Respiratory Disease Treatment Market into the following categories:

By Treatment Type: 

• Anti-Infectious Agents
  • Antibiotics           
  • Sulfas    
• Anti-Parasiticides                 
• Bronchodilators                    
• Oral Rehydration Fluids                     
• Non-Steroidal Anti-Inflammatories               
• Mucolytics

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Key market participants operating in the MEA Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale and Vétoquinol S.A.